Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest From Andrew McConaghie
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.
After a year of hype around generative AI, the question is can it deliver productivity wins for biopharma? Consultants at BCG give insights into successes and failures of early projects and emphasize that putting people first is key to success.
Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.